JP2017509683A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509683A5
JP2017509683A5 JP2016560799A JP2016560799A JP2017509683A5 JP 2017509683 A5 JP2017509683 A5 JP 2017509683A5 JP 2016560799 A JP2016560799 A JP 2016560799A JP 2016560799 A JP2016560799 A JP 2016560799A JP 2017509683 A5 JP2017509683 A5 JP 2017509683A5
Authority
JP
Japan
Prior art keywords
azetidin
quinazoline
ethylamino
trifluoromethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560799A
Other languages
English (en)
Japanese (ja)
Other versions
JP6629753B2 (ja
JP2017509683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/000525 external-priority patent/WO2015149909A1/en
Publication of JP2017509683A publication Critical patent/JP2017509683A/ja
Publication of JP2017509683A5 publication Critical patent/JP2017509683A5/ja
Application granted granted Critical
Publication of JP6629753B2 publication Critical patent/JP6629753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560799A 2014-04-03 2015-03-09 がん治療剤の組合せ Active JP6629753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974765P 2014-04-03 2014-04-03
US61/974,765 2014-04-03
PCT/EP2015/000525 WO2015149909A1 (en) 2014-04-03 2015-03-09 Combinations of cancer therapeutics

Publications (3)

Publication Number Publication Date
JP2017509683A JP2017509683A (ja) 2017-04-06
JP2017509683A5 true JP2017509683A5 (enExample) 2018-04-19
JP6629753B2 JP6629753B2 (ja) 2020-01-15

Family

ID=52692591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560799A Active JP6629753B2 (ja) 2014-04-03 2015-03-09 がん治療剤の組合せ

Country Status (15)

Country Link
US (1) US9980966B2 (enExample)
EP (1) EP3125935B1 (enExample)
JP (1) JP6629753B2 (enExample)
KR (1) KR102410696B1 (enExample)
CN (1) CN106456752B (enExample)
AR (1) AR099931A1 (enExample)
AU (1) AU2015240094B2 (enExample)
CA (1) CA2944573C (enExample)
ES (1) ES2768900T3 (enExample)
IL (1) IL248126A0 (enExample)
MX (1) MX370540B (enExample)
NZ (1) NZ725361A (enExample)
RU (1) RU2733401C2 (enExample)
SG (1) SG11201608189WA (enExample)
WO (1) WO2015149909A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302951A (en) * 2020-11-16 2023-07-01 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
AU2025220299A1 (en) * 2024-02-05 2026-07-16 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7547794B2 (en) 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
US7816353B2 (en) 2003-10-24 2010-10-19 Exelixis, Inc. P70S6 kinase modulators and method of use
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
BRPI0417498A (pt) 2003-12-09 2007-05-29 Us Gov Health & Human Serv método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EA023821B1 (ru) * 2010-11-24 2016-07-29 Мерк Патент Гмбх Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции
MX370448B (es) 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.

Similar Documents

Publication Publication Date Title
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CY1119886T1 (el) Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
JP2017530983A5 (enExample)
EA201490552A1 (ru) Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
EA201800064A1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201692298A1 (ru) Производные карбоксамидов
EA201792237A1 (ru) Фармацевтические составы
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
EA202090398A1 (ru) Фармацевтическая композиция, включающая сакубитрил и валсартан
JP2014509637A5 (enExample)
JP2015509917A5 (enExample)
JP2016537344A5 (enExample)
JOP20230099A1 (ar) تركيبات صيدلية